A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.
Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
DRUG: SPH5030
Objective response rate (ORR), Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1., Approximately 2 years
Duration of remission (DOR), DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause., Approximately 2 years|Disease control rate (DCR), DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease., Approximately 2 years|Progression-free survival (PFS), From the start date of study treatment to the date of progression disease or death , whichever occurred first., Approximately 2 years|Overall Survival (OS), Determination of the overall survival times of all patients, Approximately 2 years|Incidence of Treatment-Emergent Adverse Events, Adverse event type, incidence, duration, Approximately 2 years
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.